Invention Grant
US08541177B2 Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
失效
用磷虾胰蛋白酶 - 硬化蛋白相互作用的抑制剂治疗和诊断异常骨密度
- Patent Title: Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
- Patent Title (中): 用磷虾胰蛋白酶 - 硬化蛋白相互作用的抑制剂治疗和诊断异常骨密度
-
Application No.: US12160761Application Date: 2007-01-15
-
Publication No.: US08541177B2Publication Date: 2013-09-24
- Inventor: Alan Barry Chan
- Applicant: Alan Barry Chan
- Applicant Address: NL Enschede
- Assignee: A Chan Holding B.V.
- Current Assignee: A Chan Holding B.V.
- Current Assignee Address: NL Enschede
- Agency: Knobbe, Martens, Olson & Bear LLP
- Priority: EP06000814 20060113
- International Application: PCT/EP2007/000295 WO 20070115
- International Announcement: WO2007/080129 WO 20070719
- Main IPC: G01N33/53
- IPC: G01N33/53 ; G01N33/566 ; C12N5/00 ; C07K14/435
Abstract:
Compositions and methods of treatment for abnormal bone density are disclosed based upon the finding that sclerostin must be bound to glypican in order to inhibit bone deposition. Methods for identifying agents that inhibit the glypican-sclerostin interaction are disclosed for treatment of bone deposition disorders. Diagnostic methods are also disclosed.
Public/Granted literature
Information query
IPC分类:
